ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Levetiracetam in the Management of Bipolar Depression

This study is currently recruiting participants.
Study NCT00566150.   Last updated on July 31, 2008.   Information provided by Yale University

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Levetiracetam in the Management of Bipolar Depression
Official Title  Levetiracetam in the Management of Bipolar Depression
Brief Summary

A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.

Detailed Description
Study Phase
Study Type  Interventional
Study Design  Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Primary Outcome Measure  Change in depressive symptom scores from baseline. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measure  Change in depressive symptom scores from baseline. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Number of subjects who achieve remission. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Change in ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP). [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Condition  Bipolar Depression
Intervention  Drug: Levetiracetam
Drug: Placebo
MEDLINE PMIDs 17140277
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  50
Start Date  October 2005
Completion Date October 2008
Eligibility Criteria 

Inclusion Criteria:

  • DSM-IV diagnosis of bipolar disorder
  • Presence of a current major depressive episode on the SCID
  • Score of 17 or great on the HDRS
  • Capable of giving voluntary written consent

Exclusion Criteria:

  • Significant current substance dependence/abuse within 3 months preceding the trial
  • Active suicidal ideation
  • Pregnant/lactating mothers
  • Significant medical history
Gender Both
Ages 18 Years to 65 Years
Accepts Healthy Volunteers No
Contacts ††
Contact: Kathleen Maloney, BA     203-974-7496     kathleen.maloney@yale.edu    
Contact: Jason Chen, BA     203-974-7559     jason.chen.jc64@yale.edu    
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00566150
Organization ID 05T-681
Secondary IDs †† HIC#0508000506
Study Sponsor  Yale University
Collaborators †† Stanley Medical Research Institute
Investigators 
Principal Investigator:     Zubin Bhagwagar, MD PhD     Yale University    
Information Provided By Yale University
Verification Date July 2008
First Received Date  November 29, 2007
Last Updated Date July 31, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers